Prevention and treatment of chemotherapy- and radiotherapy-induced oral mucositis: A review

Oral Oncology

Volumn 35, Issue 5, 1999, Pages 453-470

  Plevova P ^a  

^a UNIVERSITY HOSPITAL OSTRAVA   (Czech Republic)

Author keywords

Antineoplastic agents; Chemically induced; Radiotherapy adverse effects; Stomatitis control; Stomatitis prevention

Indexed keywords

ALLOPURINOL; ALPHA TOCOPHEROL; ATROPINE; AZELASTINE; BENZYDAMINE; BETA CAROTENE; BETAMETHASONE; CHAMOMILE; CYTOKINE; FLUOROURACIL; FOLINATE CALCIUM; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROGEN PEROXIDE; ICOSANOID; IMMUNOGLOBULIN G; INDOMETACIN; INTERLEUKIN 11; KAOLIN PECTIN; MELPHALAN; MESALAZINE; METHOTREXATE; PENTOXIFYLLINE; POVIDONE IODINE; PROPANTHELINE BROMIDE; RETINOIC ACID; SILVER NITRATE; SUCRALFATE; TRANSFORMING GROWTH FACTOR BETA3; UNINDEXED DRUG;

CANCER; CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CRYOTHERAPY; DENTAL SURGERY; DOUBLE BLIND PROCEDURE; DRUG INDUCED DISEASE; HELIUM NEON LASER; HUMAN; MOUTH HYGIENE; MUCOSA INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; STOMATITIS;

ANTINEOPLASTIC AGENTS; HUMANS; ORAL HYGIENE; RADIATION INJURIES; RADIOTHERAPY; STOMATITIS;

EID: 0032766953     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1368-8375(99)00033-0     Document Type: Review

References (225)

1. National Cancer Institute US Monographs. Consensus Development Conference on Oral Complications of Cancer Therapies: Diagnosis, Prevention, and Treatment. Bethesda: National Institutes of Health, 1990.
2. Gallagher J.G. Mucositis. Klastersky J., Schimpff S.C., Lenn H.J. Handbook of Supportive Care in Cancer. 1995;147-156 Marcel Dekker, New York.
3. Overholser C.D. Jr. Oral care for the cancer patient. Klastersky J, Schimpff S.C., Lenn H.J. Handbook of Supportive Care in Cancer. 1995;125-145 Marcel Dekker, New York.
4. Sonis ST. Oral complications of cancer therapy. In: DeVita VT, Hellma S, Rosenberg SA, editors. Cancer: Principles and Practice of Oncology, 5th Edition. Philadelphia: JB Lippincott, 1993. p. 2385-93.
5. Sonis S.T. Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol. 34:1998;39-43.
6. Hallahan DE, Haimovitz-Friedman A, Kufe DW, Fuks Z, Weichselbaum RR. The role of cytokines in radiation oncology. Important Adv Oncol 1993;71-80.
7. Hallahan D., Kuchibhotla J., Wyble C. Cell adhesion molecules mediate radiation-induced leukocyte adhesion to the vascular endothelium. Cancer Res. 56:1996;5150-5155.
8. Eissner G., Lindner H., Behrends U., Kolch W., Hieke A., Klauke I, Bornkamm G.W., Holler E. Influence of bacterial endotoxin on radiation-induced activation of human endothelial cells in vitro and in vivo: protective role of IL-10. Transplantation. 62:1996;819-827.
9. Koj A. Initiation of acute phase response and synthesis of cytokines. Biochim Biophys Acta. 1317:1996;84-94.
10. Fisher D.E. Apoptosis in cancer therapy: crossing the threshold. Cell. 78:1994;539-542.
11. Meyn R.E., Stephens L.C., Milas L. Programmed cell death and radioresistance. Cancer Metastasis Rev. 15:1996;119-131.
12. Debatin K.M. Cytotoxic drugs, programmed cell death, and the immune system: defining new roles in an old play. J Natl Cancer Inst. 89:1997;750-751.
13. Berkowitz R.J., Crock J., Strickland R., Gordon E.M., Strandjord S., Coccia P.F. Oral complications associated with bone marrow transplantation in a pediatric population. Am J Pediatr Hematol Oncol. 5:1983;53-57.
14. Woo S.B., Sonis T., Monopoli M.M., Sonis A.L. A longitudinal study of oral ulcerative mucositis in bone marrow transplant recipients. Cancer. 72:1993;1612-1617.
15. Carrega G., Castagnola E., Canessa A., Argenta P., Haupt R., Dini G., Garaventa A. Herpes simplex virus and oral mucositis in children with cancer. Support Care Cancer. 2:1994;266-269.
16. Chi K.H., Chen C.H., Chan W.K., Chow K.C., Chen S.Y., Yen S.H., Chao J.Y., Chang C.Y., Chen K.Y. Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients after cisplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol. 13:1995;2620-2628.
17. Rosenberg S. Oral complications of cancer chemotherapy - a review of 398 patients. J Oral Med. 41:1986;93-97.
18. Hasenau C, Clasen BPE, Roettger D. Anwendung einer standardisierten Mundpflege zur Prophylaxe und Therapie einer Mukositis bei Patienten während der Radiochemotherapie von Kopf-Hals-Malignomen. Laryng Rhinol Otol 1988; 67:576-9.
19. Mailath G, Rasse M, Rotter M, Hollmann K. Zur Ursache der Stomatitis bei der Chemotherapie von Kopf-Hals-Tumoren. Z Stomatol 1989;86:353-9.
20. Spijkervet F.K.L., van Saene H.K.F., van Saene J.J.M., Panders A.K., Vermey A., Mehta D.M., Fidler V. Effect of selective elimination of the oral flora on mucositis in irradiated head and neck cancer patients. J Surg Oncol. 46:1991;167-173.
21. Martin M.V. Irradiation mucositis: a reappraisal. Oral Oncol Eur J Cancer. 29B:1993;1-2.
22. Symonds R.P., McIlroy P., Khorrami J., Paul J., Pyper E., Alcock S.R., McCallum I., Speekenbrink A.B., McMurray A., Lindemann E., Thomas M. The reduction of radiation mucositis by selective decontamination antibiotic pastilles: a placebo-controlled double-blind trial. Br J Cancer. 74:1996;312-317.
23. Gabrilove J.L., Jakubowski A., Scher H., Sternberg C., Wong G., Grous J., Yagoda A., Fain K., Moore M.A.S., Clarkson B., Oettgen H.F., Alton K., Welte K., Souza L. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional cell carcinoma of the urothelium. N Engl J Med. 318:1988;1414-1422.
24. LeVeque F.G., Parzuchowski J.B., Farinacci G.C., Redding S.W., Rodu B., Johnson J.T., Ferretti G.A., Eisenberg P.D., Zimmer M.B. Clinical evaluation of MGI 209, an anesthetic, film-forming agent for relief from painful oral ulcers associated with chemotherapy. J Clin Oncol. 10:1992;1963-1968.
25. Gordon B., Spadinger A., Hodges E., Ruby E., Stanley R., Coccia P. Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis after hematopoietic stem-cell transplantation. J Clin Oncol. 12:1994;1917-1922.
26. Chi K.H., Chan W.K., Shu C.H., Law C.K., Chen S.Y., Yen S.H., Chen K.Y. Elimination of dose limiting toxicities of cisplatin, 5-fluorouracil, and leucovorin using a weekly 24-hour infusion schedule for the treatment of patients with nasopharyngeal carcinoma. Cancer. 76:1995;2186-2192.
27. Ibrahim E.M., al-Mulhim F.A. Effect of granulocyte-macrophage colony-stimulating factor on chemotherapy-induced oral mucositis in non-neutropenic cancer patients. Med Oncol. 14:1997;47-51.
28. Weisdorf D.J., Bostrom B., Raether D., Mattingly M., Walker P., Pihlstrom B., Ferrieri P., Haake R., Goldman A., Woods W., Ramsay N.K.C., Kersey J.H. Oropharyngeal mucositis complicating bone marrow transplantation: prognostic factors and the effect of chlorhexidine mouth rinse. Bone Marrow Transplant. 4:1989;89-95.
29. Spijkervet F.K.L., van Saene H.K.F., Panders A.K., Vermey A., van Saene J.J.M., Mehta D.M., Fidler V. Effect of chlorhexidine rinsing on the oropharyngeal ecology in patients with head and neck cancer who have irradiation mucositis. Oral Surg Oral Med Oral Pathol. 67:1989;154-161.
30. Epstein J.B., Vickars L., Spinelli J., Reece D. Efficacy of chlorhexidine and nystatin rinses in prevention of oral complications in leukemia and bone marrow transplantation. Oral Surg Oral Med Oral Pathol. 73:1992;682-689.
31. Foote R.L., Loprinzi C.L., Frank A.R., O'Fallon J.R., Gulavita S., Tewfik H.H., Ryan M.A., Earle J.M., Novotny P. Randomized trial of a chlorhexidine mouthwash for alleviation of radiation-induced mucositis. J Clin Oncol. 12:1994;2630-2633.
32. Bondi E., Baroni C., Prete A., Gatti M., Carrassi A., Lodi G., Porter S.R. Local antimicrobial therapy of oral mucositis in paediatric patients undergoing bone marrow transplantation. Oral Oncol. 33:1997;322-326.
33. Okuno S.H., Foote R.L., Loprinzi C.L., Gulavita S., Sloan J.A., Earle J., Novotny P.J., Burk M., Frank A.R. A randomized trial of a nonabsorbable antibiotic lozenge given to alleviate radiation-induced mucositis. Cancer. 79:1997;2193-2199.
34. Wilkes J.D. Prevention and treatment of oral mucositis following cancer chemotherapy. Semin Oncol. 25:1998;538-551.
35. Wright W.E., Haller J.M., Harlow S.A., Pizzo P.A. An oral disease prevention program for patients receiving radiation and chemotherapy. J Am Dent Assoc. 110:1985;43-47.
36. Sonis S., Kunz A. Impact of improved dental services on the frequency of oral complications of cancer therapy for patients with non-head-and-neck malignancies. Oral Surg Oral Med Oral Pathol. 65:1988;19-22.
37. National Institutes of Health consensus development conference statement: oral complications of cancer therapies: diagnosis, prevention, and treatment. J Am Dent Assoc. 119:1989;179-183.
38. Jansma J., Vissink A., Spijkervet F.K.L., Roodenburg J.L.N., Panders A.K., Vermey A., Szabó B.G., Gravenmade E.J. Protocol for the prevention and treatment of oral sequelae resulting from head and neck radiation therapy. Cancer. 70:1992;2171-2180.
39. Whitmyer C.C., Esposito S.J., Terezhalmy G.T. Radiotherapy for head and neck neoplasms. Gen Dent. 45:1997;363-370.
40. Borowski B., Benhamou E., Pico J.L., Laplanche A., Margainaud J.P., Hayat M. Prevention of oral mucositis in patients treated with high-dose chemotherapy and bone marrow transplatation: a randomised controlled trial comparing two protocols of dental care. Eur J Cancer B Oral Oncol. 30B:1994;93-97.
41. Carl W., Emrich L.S. Management of oral mucositis during local radiation and systemic chemotherapy: a study of 98 patients. J Prosthet Dent. 66:1991;361-369.
42. Bernhof C.H., Skaug N. Oral findings in irradiated edentulous patients. Int J Oral Surg. 14:1985;416-427.
43. Carl W. Oral complications of local and systemic cancer treatment. Curr Opin Oncol. 7:1995;320-324.
44. Feber T. Management of mucositis in oral irradiation. Clin Oncol R Coll Radiol. 8:1996;106-111.
45. Shieh S.H., Wang S.T., Tsai S.T., Tseng C.C. Mouth care for nasopharyngeal cancer patients undergoing radiotherapy. Oral Oncol. 33:1997;36-41.
46. Richardson C.T. Sucralfate. Ann Intern Med. 97:1982;269-272.
47. Nagashima R., Yoshida N., Terao N. Sucralfate, a basic aluminum salt of sucrose sulfate. II. Inhibition of peptic hydrolysis as it results from sucrose sulfate interaction with protein substrate, serum albumins. Arzneimittelforschung. 29:1979;73-76.
48. Nagashima R., Hirano T. Selective binding of sucralfate to ulcer lesion. I. Experiments in rats with acetic acid-induced gastric ulcer receiving unlabelled sucralfate. Arzneimittelforschung. 30:1980;80-83.
49. Szabo S., Hollander D. Pathways of gastrointestinal protection and repair: mechanisms of action of sucralfate. Am J Med. 86:1989;23-31.
50. Szabo S., Vattay P., Scarbrough E., Folkman J. Role of vascular factors including angiogenesis in the mechanisms of action of sucralfate. Am J Med. 91:1991;158-160.
51. Ferraro J.M., Mattern J.Q.A. II. Sucralfate suspension for stomatitis. Drug Intell Clin Pharm. 18:1984;153. (letter).
52. Ferraro J.M. Sucralfate suspension for mouth ulcers. Drug Intell Clin Pharm. 19:1985;480. (letter).
53. Solomon M.A. Oral sucralfate suspension for mucositis. N Engl J Med. 315:1986;459-460. (letter).
54. Pfeiffer P., Madsen E.L., Hansen O., May O. Effect of prophylactic sucralfate suspension on stomatitis induced by cancer chemotherapy. A randomized, double-blind cross-over study. Acta Oncol. 29:1990;171-173.
55. Scherlacher A, Beaufort-Spontin F. Strahlentherapie von Kopf-Hals-Malignomen: Entzündungsprophylaxe der Schleimhaut durch Sucralfatbehandlung. HNO 1990;38:24-8.
56. Allison R.R., Vongtama V., Vaughan J., Shin K.H. Symptomatic acute mucositis can be minimized or prophylaxed by the combination of sucralfate and fluconazole. Cancer Invest. 13:1995;16-22.
57. Franzén L., Henriksson R., Littbrand B., Zackrisson B. Effects of sucralfate on mucositis during and following radiotherapy of malignancies in the head and neck region. Acta Oncologica. 34:1995;219-223.
58. Giorgi F., Bascioni R., De Signoribus G., Di-Saverio F. Sucralfate prophylaxis of fluorouracil-induced stomatitis. Tumori. 82:1996;585-587.
59. Shenep J.L., Kalwinsky D.K., Hutson P.R., George S.L., Dodge R.K., Blankenship K.R., Thornton D. Efficacy of oral sucralfate suspension in prevention and treatment of chemotherapy-induced mucositis. J Pediatr. 113:1988;758-763.
60. Epstein J.B., Wong F.L. The efficacy of sucralfate suspension in the prevention of oral mucositis due to radiation therapy. Int J Radiat Oncol Biol Phys. 28:1994;693-698.
61. Makkonen T.A., Bostrom P., Vilja P., Joensuu H. Sucralfate mouth washing in the prevention of radiation-induced mucositis: a placebo-controlled double-blind randomized study. Int J Radiat Oncol Biol Phys. 30:1994;177-182.
62. Loprinzi C.L., Ghosh C., Camoriano J., Sloan J., Steen P.D., Michalak J.C., Schaefer P.L., Novotny P.J., Gerstner J.B., White D.F., Hatfield A.K., Quella S.K. Phase III controlled evaluation of sucralfate to alleviate stomatitis in patients receiving fluorouracil-based chemotherapy. J Clin Oncol. 15:1997;1235-1238.
63. Meredith R., Salter M., Kim R., Spencer S., Weppelmann B., Rodu B., Smith J., Lee J. Sucralfate for radiation mucositis: results of a double-blind randomized trial. Int J Radiat Oncol Biol Phys. 37:1997;275-279.
64. Barker G., Loftus L., Cuddy P., Barker B. The effects of sucralfate suspension and dihenhydramine syrup plus kaolin-pectin on radiotherapy-induced mucositis. Oral Surg Oral Med Oral Pathol. 71:1991;288-293.
65. Tampo Y., Yonaha M. Vitamin E and glutathione are required for preservation of microsomal glutathione s-transferase from oxidative stress in microsomes. Pharmacol Toxicol. 66:1990;259-265.
66. Kagan V., Serbinova E., Packer L. Antioxidant effects of ubiquinones in microsomes and mitochondria are mediated by tocopherol recycling. Biochem Biophys Res Commun. 169:1990;851-857.
67. Wilson JD. Vitamin deficiency and excess. In: Wilson JD, Braunwald E, Isselbacher KJ, Petersdorf RG, Martin JB, Fauci AS, Root RK, editors. Harrison's Principles of Internal Medicine, I, 12th Edition. New York: McGraw-Hill, 1991. p. 434-45.
68. Schreck R., Rieber P., Baeuerle P.A. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-κB transcription factor and HIV-1. EMBO J. 10:1991;2247-2258.
69. Wadleigh R.G., Redman R.S., Graham M.L., Krasnow S.H., Anderson A, Cohen M.H. Vitamin E in the treatment of chemotherapy-induced mucositis. Am J Med. 92:1992;481-484.
70. Lopez I, Goudou C, Ribrag V, Sauvage C, Hazebroucq G, Dreyfus F. Traitement des mucites par la vitamine E lors de l'administration d'anti-neoplastiques neutropeniants. Ann Med Interne Paris 1994;145:405-8.
71. Prutkin L. Wound healing and vitamin A acid. Acta Dermatol Venereol. 52:1972;489-492.
72. Orfanos C.E., Bauer R. Evidence for anti-inflammatory activities of oral synthetic retinoids: experimental findings and clinical experience. Br J Dermatol. 109:1983;55-60.
73. Sporn M.B., Roberts A.B. Regulation of cell differentiation and proliferation by retinoids and transforming growth factor β Burger M.M., Sordat B., Zinkenagel R.M. Cell to Cell Interaction. 1990;2-15 Karger, Basel.
74. Cohen G., Elad S., Or R., Galili D., Garfunkel A.A. The use of tretinoin as oral mucositis prophylaxis in bone marrow transplantation patients: a preliminary study. Oral Dis. 3:1997;243-246.
75. Daeffler R. Oral hygiene measures for patients with cancer. Cancer Nurs. 3:1980;347-356.
76. Dudjak L.A. Mouth care for mucositis due to radiation therapy. Cancer Nurs. 10:1987;131-140.
77. McGaw W.T., Belch A. Oral complications of acute leukemia: prophylactic impact of chlorhexidine mouth rinse regimen. Oral Surg Oral Med Oral Pathol. 60:1985;275-280.
78. Ferretti G.A., Ash R.C., Brown A.T., Parr M.D., Romond E.H., Lillich T.T. Control of oral mucositis and candidiasis in marrow transplantation: a prospective, double-blind trial of chlorhexidine digluconate oral rinse. Bone Marrow Transplant. 3:1988;483-493.
79. Ferretti G.A., Raybould T.P., Brown A.T., MacDonald J.S., Greenwood M., Maruyama Y., Geil J., Lillich T.T., Ash R.C. Chlorhexidine prophylaxis for chemotherapy- and radiotherapy-induced stomatitis: a randomized double-blind trial. Oral Surg Oral Med Oral Pathol. 69:1990;331-338.
80. Rutkauskas J.S., Davis J.W. Effects of chlorhexidine during immunosuppressive chemotherapy: a preliminary report. Oral Surg Oral Med Oral Pathol. 76:1993;441-448.
81. Wahlin B.Y. Effects of chlorhexidine mouthrinse on oral health in patients with acute leukemia. Oral Surg Oral Med Oral Pathol. 68:1989;279-287.
82. Dodd M.J., Larson P.J., Dibble S.L., Miaskowski C., Greenspan D., MacPhail L., Hauck W.W., Paul S.M., Ignoffo R., Shiba G. Randomized clinical trial of chlorhexidine versus placebo for prevention of oral mucositis in patients receiving chemotherapy. Oncol Nurs Forum. 23:1996;921-927.
83. Rahn R., Adamietz I.A., Böttcher H.D., Schäfer V., Reimer K., Fleischer W. Povidone-iodine to prevent mucositis in patients during antineoplastic radiochemotherapy. Dermatology. 195(Suppl. 2):1997;57-61.
84. Martin M.V., Al-Tikriti U., Bramley P.A. Yeast flora of the mouth and skin during and after irradiation for oral and laryngeal cancer. J Med Microbiol. 14:1981;457-467.
85. Pau HW, Strähler-Pohl HJ, Exner M. Hefepilzflora bei der Radiotherapie von Tumoren den oberen Aerodigestiven Trakt. HNO 1985;33:485-8.
86. Wade J.C., Schimpff S.C. Epidemiology and prevention of Candida infection. Bodey G.P., Famstein V. Candidosis. 1985;111-113 Raven Press, New York.
87. Bernhoft C.H., Skaug N. Oral findings in irradiated edentulous patients. Int J Oral Surg. 14:1985;416-427.
88. Ferretti G.A., Brown A.T., Lillich T.T., Ash R.C., Largent B.M. The effect of chlorhexidine on the oral microflora of bone marrow transplant patients. J Dent Res. 64(Suppl. 6):1985;235.
89. Matthews R.H., Ercal N. Prevention of mucositis in irradiated head and neck cancer patients. J Exp Ther Oncol. 1:1996;135-138.
90. Thiemer K., Stadler R., Isaac O. Biochemical investigations of the camomile. Arzneimittelforschung. 23:1973;756-759.
91. Fidler P., Loprinzi C.L., O'Fallon J.R., Leitch J.M., Lee J.K., Hayes D.L., Novotny P., Clemens-Schutjer D., Bartel J., Michalak J.C. Prospective evaluation of a chamomile mouthwash for prevention of 5-FU-induced oral mucositis. Cancer. 77:1996;522-525.
92. Scheinman R.I., Gualberto A., Jewell C.M., Cidlowski J.A., Baldwin A.S. Jr. Characterization of mechanisms involved in transrepression of NF-κB by activated glucocorticoid receptors. Mol Cell Biol. 15:1995;943-953.
93. Barnes P.J., Karin M. Nuclear factor-κB - a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 336:1997;1066-1071.
94. Abdelaal A.S., Barker D.S., Fergusson M.M. Treatment for irradiation-induced mucositis. Lancet. l:1989;97. (letter).
95. Hunter K.M. A clinical evaluation of benzydamine hydrochloride. Aust Dent J. 23:1978;164-166.
96. Kataoka S., Nishimura K., Naito T. In vivo metabolism and anti-inflammatory activity of benzydamine hydrochloride in rats treated with carrageenin. Chem Pharm Bull (Tokyo). 27:1979;2890-2903.
97. Whiteside M.W. A controlled study of benzydamine oral rinse ("Difflam") in general practice. Curr Med Res Opin. 8:1982;188-190.
98. Kim J.H., Chu F.C., Lakshmi V., Houde R. Benzydamine HCl, a new agent for the treatment of radiation mucositis of the oropharynx. Am J Clin Oncol. 9:1986;132-134.
99. Prada A., Chiesa F. Effects of benzydamine on the oral mucositis during antineoplastic radiotherapy and/or intra-arterial chemotherapy. Int J Tiss Reac. 9:1987;115-119.
100. Epstein J.B., Stevenson-Moore P., Jackson S., Mohamed J.H., Spinelli J.J. Prevention of oral mucositis in radiation therapy: a controlled study with benzydamine hydrochloride rinse. Int J Radiat Oncol Biol Phys. 16:1989;1571-1575.
101. Samaranayake L.P., Robertson A.G., MacFarlane T.W., Hunter I.P., MacFarlane G., Soutar D.S., Ferguson M.M. The effect of chlorhexidine and benzydamine mouthwashes on mucositis induced by therapeutic irradiation. Clin Radiol. 39:1988;291-294.
102. Schubert M.M., Newton R.E. The use of benzydamine HCl for the management of cancer therapy-induced mucositis: preliminary report of a multicentre study. Int J Tissue Reac. 9:1987;99-103.
103. Epstein J.B., Stevenson-Moore P. Benzydamine hydrochloride in prevention and management of pain in oral mucositis associated with radiation therapy. Oral Surg Oral Med Oral Pathol. 62:1986;145-148.
104. Lever S.A., Dupuis L.L., Chan S.L. Comparative evaluation of benzydamine oral rinse in children with antineoplastic-induced stomatitis. Drug Intell Clin Pharm. 21:1987;359-361.
105. Glickman RM. Inflammatory bowel disease. Ulcerative colitis and Crohn's disease. In: Wilson JD, Braunwald E, Isselbacher KJ, Petersdorf RG, Martin JB, Fauci AS, Root RK, editors. Harrison's Principles of Internal Medicine, II, 12th Edition. New York: McGraw-Hill, 1991. p. 1268-81.
106. Kopp E., Ghosh S. Inhibition of NF-κB by sodium salicylate and aspirin. Science. 265:1994;956-959.
107. Collier P.M., Neill S.M., Copeman P.W. Topical 5-aminosalicylic acid: a treatment for aphthous ulcers. Br J Dermatol. 126:1992;185-188.
108. Ranzi T., Campanini M., Bianchi P. Sucessful treatment of genital and oral ulceration in Behcet's disease with topical 5-aminosalicylic acid (5-ASA). Br J Dermatol. 120:1989;471. (letter).
109. Rymes N., Glick L., Holmes J.A. Topical mesalazine in the treatment of chemotherapy and radiotherapy-induced oral mucositis. Bone Marrow Transplant. 18:1996;484. (letter).
110. Cartee L., Petros W.P., Rosner G.L., Gilbert C., Moore S., Affronti M.L., Hoke J.A., Hussein A.M., Ross M., Rubin P., Vredenburgh J.J., Peters W.P. Evaluation of GM-CSF for prevention of chemotherapy-induced mucositis: a randomized, double-blind, dose-ranging study. Cytokine. 7:1995;471-477.
111. Cox D.A., Maurer T. Transforming growth factor-β Clin Immunol Immunopathol. 83:1997;25-30.
112. Sonis S.T., Lindquist L., van Vugt V., Stewart A.A., Stam K., Qu G.Y., Iwata K.K., Haley J.D. Prevention of chemotherapy-induced ulcerative mucositis by transforming growth factor β3. Cancer Res. 54:1994;1135-1138.
113. Sonis S.T., van Vugt A.G., Brien J.P., Muska A.D., Bruskin A.M., Rose A., Haley J.D. Transforming growth factor-β3 mediated modulation of cell cycling and attenuation of 5-fluorouracil induced oral mucositis. Oral Oncol. 33:1997;47-54.
114. Cohen S. The epidermal growth factor (EGF). Cancer. 51:1983;1787-1791.
115. Epstein J.B., Emerton S., Guglietta A., Le N. Assessment of epidermal growth factor in oral secretions of patients receiving radiation therapy for cancer. Oral Oncol. 33:1997;359-363.
116. Girdler N.M., McGurk M., Aqual S., Prince M. The effect of epidermal growth factor mouthwash on cytotoxic-induced oral ulceration. A phase I clinical trial. Am J Clin Oncol. 18:1995;403-406.
117. Pastuszak A.L., Schüler L., Speck-Martins C.E., Coelho K.E.F.A., Cordello S.M., Vargas F., Brunoni D., Schwarz I.V.D., Larrandabaru M., Safattle H., Meloni V.F.A., Koren G. Use of misoprostol during pregnancy and Möbius' syndrome in infants. N Engl J Med. 338:1998;1881-1885.
118. Duenas-Gonzalez A., Sobrevilla-Calvo P., Frias-Medivil M., Gallardo-Rincon D., Lara-Medina F., Aguilar-Ponce L., Miranda-Lopez E., Zinser-Sierra J., Reynoso-Gomez E. Misoprostol prophylaxis for high-dose chemotherapy-induced mucositis: a randomized double-blind study. Bone Marrow Transplant. 17:1996;809-812.
119. Johansson C., Bergstrom S. Prostaglandins and protection of gastroduodenal mucosa. Scand J Gastroenterol. 77:1982;21-46.
120. 2 enhances healing of chemotherapy associated mucosal lesions. Lancet. I:1986;622. (letter).
121. Porteder H., Rausch E., Kment G., Watzek G., Matejka M., Sinzinger H. Local prostaglandin E2 in patients with oral malignancies undergoing chemo- and radiotherapy. J Craniomaxillofac Surg. 16:1988;371-374.
122. 2 in radiochemotherapy-induced oral mucositis. Br J Oral Maxillofac Surg. 28:1990;89-91.
123. 2 for prophylaxis of oral mucositis following BMT. Bone Marrow Transplant. 11:1993;379-382.
124. Fiocchi C. Cytokines and intestinal inflammation. Transplant Proc. 28:1996;2442-2443.
125. Czuszak C.A., Sutherland D.E., Billman M.A., Stein S.H. Prostaglandin E2 potentiates interleukin-1 beta induced interleukin-6 production by human gingival fibroblasts. J Clin Periodontol. 23:1996;635-640.
126. Rothwell B.R., Spektor W.S. Palliation of radiation-related mucositis. Spec Care Dentist. 10:1990;21-25.
127. Simon A.R., Roberts M.W. Management of oral complications associated with cancer therapy in pediatric patients. ASDC J Dent Child. 58:1991;384-389.
128. Maciejewski B., Zajusz A., Pilecki B., Swiatnicka J., Skladowski K., Dorr W., Kummermehr J., Trott K.F. Acute mucositis in the stimulated oral mucosa of patients during radiotherapy for head and neck cancer. Radiother Oncol. 22:1991;7-11.
129. Maciejewski B., Skladowski K., Zajusz A. Radiobiological predictors of tumor and acute normal tissue response in radiotherapy for head and neck cancers. Neoplasma. 38:1991;513-522.
130. Dorr W., Jacubek A., Kummermehr J., Herrmann T., Dolling-Jochem I., Eckelt U. Effects of stimulated repopulation on oral mucositis during conventional radiotherapy. Radiother Oncol. 37:1995;100-107.
131. Ackland S.P., Schilsky R.L. High-dose methotrexate: a critical reappraisal. J Clin Oncol. 5:1987;2017-2031.
132. Oliff A., Bleyer W.A., Poplack D.G. Methotrexate-induced oral mucositis and salivary methotrexate concentrations. Cancer Chemother Pharmacol. 2:1979;225-226.
133. Rask C., Albertioni F., Schrøder H., Peterson C. Oral mucositis in children with acute lymphoblastic leukemia after high-dose methotrexate treatment without delayed elimination of methotrexate: relation to pharmacokinetic parametres of methotrexate. Pediatr Hematol Oncol. 13:1996;359-367.
134. Albertioni F., Rask C., Schroeder H., Peterson C., Monitoring of methotrexate 7-hydroxymethotrexate in saliva from children with acute lymphoblastic leukemia receiving high-dose consolidation treatment: relation to oral mucositis Anticancer Drugs. 8:1997;119-124.
135. Fox R.M., Woods R.L., Tattersall M.H.N., Brodie G.M. Allopurinol modulation of high-dose fluorouracil toxicity. Lancet. I:1979;677. (letter).
136. Schwartz P.M., Dunigan J.M., Marsh J.C., Handschumacher R.E. Allopurinol modification of the toxicity and antitumor activity of 5-fluorouracil. Cancer Res. 40:1980;1885-1889.
137. Howell S.B., Wung W.E., Taetle R., Hussain F., Romine J.S. Modulation of 5-fluorouracil toxicity by allopurinol in man. Cancer. 48:1981;1281-1289.
138. Nakamura K., Natsugoe S., Kumanohoso T., Shinkawa T., Kariyazono H., Yamada K., Baba M., Yoshinaka H., Fukumoto T., Aikou T. Prophylactic action of allopurinol against chemotherapy-induced stomatitis - inhibition of superoxide dismutase and proteases. Anticancer Drugs. 7:1996;235-239.
139. Clark P.I., Slevin M.L. Allopurinol mouthwashes and 5-fluorouracil induced oral toxicity. Eur J Surg Oncol. 11:1985;267-268.
140. Tsavaris N., Caragiauris P., Kosmidis P. Reduction of oral toxicity of 5-fluorouracil by allopurinol mouthwashes. Eur J Surg Oncol. 14:1988;405-406.
141. Porta C., Moroni M., Nastasi G. Allopurinol mouthwashes in the treatment of 5-fluorouracil-induced stomatitis. Am J Clin Oncol. 17:1994;246-247.
142. Loprinzi C.L., Cianflone S.G., Dose A.M., Etzell P.S., Burnham N.L., Therneau T.M., Hagen L., Gainey D.K., Cross M., Athmann L.M., Fischer T., O'Connell M.J. A controlled evaluation of an allopurinol mouthwash as prophylaxis against 5-fluorouracil-induced stomatitis. Cancer. 65:1990;1879-1882.
143. New shield protects oral tissues during radiation. J Am Dent Assoc 1994;125:508 (news).
144. Perch S.J., Machtay M., Markiewicz D.A., Klingerman M.M. Decreased acute toxicity by using midline mucosa-sparing blocks during radiation therapy for carcinoma of the oral cavity, oropharynx, and nasopharynx. Radiology. 197:1995;863-866.
145. Mahood D.J., Dose A.M., Loprinzi C.L., Veeder M.H., Athmann L.M., Therneau T.M., Sorenson J.M., Gainey D.K., Mailliard J.A., Gusa N.L., Finck G.K., Johnson C., Goldberg R.M. Inhibition of fluorouracil-induced stomatitis by oral cryotherapy. J Clin Oncol. 9:1991;449-452.
146. Cascinu S., Fedeli A., Fedeli S.L., Catalano G. Oral cooling (cryotherapy), an effective treatment for the prevention of 5-fluorouracil-induced stomatitis. Oral Oncol Eur J Cancer. 30B:1994;234-236.
147. Sato A, Kumagai S, Sakaki K, Morikawa H, Song ST, Mori S. Inhibition of 5-fluorouracil-cisplatin-induced stomatitis by oral cryotherapy: use of an ice-bar containing fibrinolysin and deoxyribonuclease combine (Elase). Gan To Kagaku Ryoho 1997;24:1135-9.
148. Rocke L.K., Loprinzi C.L., Lee J.K., Kunselman S.J., Iverson R.K., Finck G., Lifsey D., Glaw K.C., Stevens B.A., Hatfield A.K., Vaught N.L., Bartel J., Pierson N. A randomized clinical trial of two different durations of oral cryotherapy for prevention of 5-fluorouracil related stomatitis. Cancer. 72:1993;2234-2238.
149. Dumontet C., Sonnet A., Bastion Y., Salles G., Espinouse D., Coiffier B. Prevention of high dose L-PAM-induced mucositis by cryotherapy. Bone Marrow Transplant. 14:1994;492-494. (letter).
150. Meloni G., Capria S., Proia A., Trisolini S.M., Mandelli F. Ice pops to prevent melphalan-induced stomatitis. Lancet. 347:1996;1691-1692.
151. Basford J.R. Low energy laser therapy: controversies and new research findings. Mayo Clin Proc. 61:1986;671-675.
152. King P.R. Low level laser therapy: a review. Laser Med Sci. 4:1989;141-149.
153. Ciais G, Namer M, Schneider M, Demard F, Pourreau-Schneider N, Martin PM, Soudry M, Franquin JC, Zattara H. La lasertherapie dans la prevention et le traitement des mucites liees a la chimiotherapie anticancereuse. Bull Cancer 1992;79:183-91.
154. Pourreau-Scheider N., Soudry M., Franquin J.C., Zattara H., Martin P.M., Ciais G., Namer M., Schneider M., Chauvel P., Demard F. Soft-laser therapy for iatrogenic mucositis in cancer patients receiving high-dose fluorouracil: a preliminary report. J Natl Cancer Inst. 84:1992;358-359.
155. Barasch A., Peterson D.E., Tanzer J.M., D'Ambrosio J.A., Nuki K., Schubert M.M., Franquin J.C., Clive J., Tutschka P. Helium-neon laser effects on conditioning-induced oral mucositis in bone marrow transplantation patients. Cancer. 76:1995;2550-2556.
156. Cowen D., Tardieu C., Schubert M., Peterson D., Resbeut M., Faucher C., Franquin J.C. Low energy Helium-Neon laser in the prevention of oral mucositis in patients undergoing bone marrow transplant: results of a double blind randomized trial. Int J Radiat Oncol Biol Phys. 38:1997;697-703.
157. Mills E.E.D. The modifying effect of beta-carotene on radiation and chemotherapy-induced oral mucositis. Br J Cancer. 57:1988;416-417.
158. Garewal H.S., Meyskens F.L., Killen D., Reeves D., Kiersch T.A., Elletson H., Strosberg A., King D., Steinbronn K. Response of oral leukoplakia to beta-carotene. J Clin Oncol. 8:1990;1715-1720.
159. 3HBA mouse tumor due to X-ray therapy combined with supplemental β-carotene or vitamin A. J Natl Cancer Inst. 71:1983;409-417.
160. Osaki T., Ueta E., Yoneda K., Hirota J., Yamamoto T. Prophylaxis of oral mucositis associated with chemoradiotherapy for oral carcinoma by Azelastine hydrochloride (Azelastine) with other antioxidants. Head Neck. 16:1994;331-339.
161. Horak F. Seasonal allergic rhinitis. Newer treatment approaches. Drugs. 45:1993;518-527.
162. Han J., Thompson P., Beutler B. Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J Exp Med. 172:1990;391-394.
163. Tilg H., Eibl B., Pichl M., Gachter A., Herold M., Brankova J., Huber C., Niederwieser D. Immune response modulation by pentoxifylline in vitro. Transplantation. 56:1993;196-201.
164. Holler E., Kolb H.J., Möller A., Kempeni J., Liesenfeld S., Pechumer H., Lehmacher W., Ruckdeschel G., Gleixner B., Riedner C. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood. 75:1990;1011-1016.
165. Bianco J.A., Appelbaum F.R., Nemunaitis J., Almgren J., Andrews F., Kettner P., Shields A., Singer J.W. Phase I-II trial of pentoxifylline for the prevention of transplant-related toxicities following bone marrow transplantation. Blood. 78:1991;1205-1211.
166. Stockschlader M., Kalhs P., Peters S., Zeller W., Kruger W., Kabisch H., Lechner K., Zander A. Intravenous pentoxifylline failed to prevent transplant-related toxicities in allogeneic bone marrow transplant recipients. Bone Marrow Transplant. 12:1993;357-362.
167. Clift R.A., Bianco J.A., Appelbaum F.R., Buckner C.D., Singer J.W., Bakke L., Bensinger W.I., Bowden R.A., McDonald G.B., Schubert M., Shields A.F., Slattery J.T., Storb R., Fisher L.D., Mori M., Thomas E.D., Hansen J.A. A randomized controlled trial of pentoxifylline for the prevention of regimen-related toxicities in patients undergoing allogeneic marrow transplantation. Blood. 82:1993;2025-2030.
168. Attal M., Huguet F., Rubie H., Charlet J.P., Schlaifer D., Huynh A., Laurent G., Pris J. Prevention of regimen-related toxicities after bone marrow transplantation by pentoxifylline: a prospective, randomized trial. Blood. 82:1993;732-736.
169. van der Jagt R.H.C., Pari G., McDiarmid S.A., Boisvert D.M., Huebsch L.B. Effect of pentoxifylline on regimen related toxicity in patients undergoing allogeneic or autologous bone marrow transplantation. Bone Marrow Transplant. 13:1994;203-207.
170. Verdi C.J., Garewal H.S., Koenig L.M., Vaughn B., Burkhead T. A double-blind, randomized, placebo-controlled, crossover trial of pentoxifylline for the prevention of chemotherapy-induced oral mucositis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 80:1995;36-42.
171. Pillsbury H.C. 3rd, Webster W.P., Rosenman J.G. Prostaglandin inhibitor and radiotherapy in advanced head and neck cancers. Arch Otolaryng Head Neck Surg. 112:1986;552-553.
172. Schedler M, Feidt H, Niewaldt M. Lässt sich die radiogene Mukositis mit Immunglobulinen behandeln? Zentralbl Hals Ohren Heilkd Kopf Haslchir 1990;139:3-4.
173. Proske H, Pfab R. Immunglobulinpräparate als antiinflammatorische Therapeutika in der Strahlentherapie. Med Welt 1992;43:1025-6.
174. Schedler MGJ, Bost P, Federspil P, Pautler M, Schätzle W. Die Behandlung der strahleninduzierten Mukositis bei Kopf-/Halstumoren mit intramuskulär verabreichtem polyvalentem Immunglobulin. Tumor Diagn Ther 1994;15:184-91.
175. Mose S., Adamietz I.A., Saran F., Thilmann C., Heyd R., Knecht R., Bottcher H.D. Can prophylactic application of immunoglobulin decrease radiotherapy-induced oral mucositis? Am J Clin Oncol. 20:1997;407-411.
176. Plevová P., Blažek B. Intravenous immunoglobulin as prophylaxis of chemotherapy-induced oral mucositis. J Natl Cancer Inst. 89:1997;326-327.
177. Nydegger U. Alte und neue Aspekte der intravenösen Immunglobulintherapie. Schweiz Med Wochenschr 1994:124:5-25.
178. Wolf H.M., Eibl M.M. Immunomodulatory effect of immunoglobulins. Clin Exp Rheumatol. 14(Suppl. 15):1996;S17-25.
179. Kekow J., Reinhold D., Pap T., Ansorge S. Intravenous immunoglobulins and transforming growth factor β Lancet. 351:1998;184-185.
180. Ahmed T., Engelking C., Szalyga J., Helson L., Coombe N., Cook P., Corbi D., Puccio C., Chun H., Mittelman A. Propantheline prevention of mucositis from etoposide. Bone Marrow Transplant. 12:1993;131-132.
181. Oblon D.J., Paul S.R., Oblon M.B., Malik S. Propantheline protects the oral mucosa after high-dose ifosfamide, carboplatin, etoposide and autologous stem cell transplantation. Bone Marrow Transplant. 20:1997;961-963.
182. Sheridan W.P., Morstyn G., Wolf M., Dodds A., Lusk J., Maher D., Layton J.E., Green M.D., Souza L., Fox R.M. Granulocyte colony-stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone marrow transplantation. Lancet. 2:1989;891-895.
183. Hermann F., Schulz G., Wieser M., Kolbe K., Nicolay U., Noack M., Lindemann A., Mertelsmann R. Effect of granulocyte-macrophage colony stimulating factor on neutropenia and related morbidity induced by myelotoxic chemotherapy. Am J Med. 88:1990;619-624.
184. Ho A.D., Del Valle F., Haas R., Engelhard M., Hiddemann W., Ruckle H., Schlimok G., Thiel E., Andreesen R., Fiedler W. Sequential studies on the role of mitoxantrone, high-dose cytarabine, and recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of refractory non-Hodgkin s lymphoma. Semin Oncol. 17(Suppl. 10):1990;14-19.
185. Grem J.L., McAtee N., Murphy R.F., Hamilton J.M., Balis F., Steinberg S., Arbuck S.G., Setser A., Jordan E., Chen A., Kohler D.R., Kotite B., Allegra C.J. Phase I and pharmacokinetic study of recombinant human granulocyte-macrophage colony-stimulating factor given in combination with fluorouracil plus calcium leucovorin in metastatic gastrointestinal adenocarcinoma. J Clin Oncol. 12:1994;560-568.
186. Atkinson K., Biggs J.C., Downs K., Juttner C., Bradstock K., Lowenthal R.M., Dale B., Szer J. GM-CSF after allogeneic bone marrow transplantation: accelerated recovery of neutrophils, monocytes and lymphocytes. Aust NZ J Med. 21:1991;686-692.
187. Pettengell R., Gurney H., Radford J.A., Deakin D.P., James R., Wilkinson P.M., Kane K., Bentley J., Crowther D. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood. 80:1992;1430-1436.
188. Locatelli F., Pession A., Zecca M., Bonetti F., Prete L., Carra A.M., Prete A., Montagna D., Comoli P., Taibi R.M., Paolucci G. Use of recombinant human granulocyte colony-stimulating factor in children given allogeneic bone marrow transplantation for acute or chronic leukemia. Bone Marrow Transplant. 17:1996;31-37.
189. Nemunaitis J., Rosenfeld C.S., Ash R., Freedman M.H., Deeg H.J., Appelbaum F., Singer J.W., Flomenberg N., Dalton W., Elfenbein G.J. Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation. Bone Marrow Transplant. 15:1995;949-954.
190. Katano M., Nakamura M., Matsuo T., Iyama A., Hisatsugu T. Effect of granulocyte colony-stimulating factor (G-CSF) on chemotherapy-induced oral mucositis. Surg Today. 25:1995;202-206.
191. Kannan V., Bapsy P.P., Anantha N., Doval D.C., Vaithianathan H., Banumathy G., Reddy K.B., Kumaraswamy S.V., Shenoy A.M. Efficacy and safety of granulocyte macrophage-colony stimulating factor (GM-CSF) on the frequency and severity of radiation mucositis in patients with head and neck carcinoma. Int J Radiat Oncol Biol Phys. 37:1997;1005-1010.
192. Rosso M., Blasi G., Gherlone E., Rosso R. Effect of granulocyte-macrophage colony-stimulating factor on prevention of mucositis in head and neck cancer patients treated with chemo-radiotherapy. J Chemother. 9:1997;382-385.
193. Keith J.C. Jr., Albert L., Sonis S.T., Pfeiffer C.J., Schaub R.G. IL-11, a pleiotropic cytokine: exciting new effects of IL-11 on gastrointestinal mucosal biology. Stem Cells. 12(Suppl. 1):1994;79-89.
194. Sonis S., Muska A., O'Brien J., Van Vugt A., Langer-Safer P., Keith J. Alteration in the frequency, severity and duration of chemotherapy-induced mucositis in hamsters by interleukin-11. Eur J Cancer B Oral Oncol. 31B:1995;261-266.
195. Sonis S.T., Van Vugt A.G., McDonald J., Dotoli E., Schwertschlag U., Szklut P., Keith J. Mitigating effects of interleukin 11 on consecutive courses of 5-fluorouracil-induced ulcerative mucositis in hamsters. Cytokine. 9:1997;605-612.
196. Rand K.H., Kramer B., Johnson A.C. Cancer chemotherapy associated symptomatic stomatitis: role of HSV (herpes simplex virus). Cancer. 50:1982;1262-1265.
197. Gluckman E., Lotsberg J., Devergie A., Zhao X.M., Melo R., Gomez-Morales M., Mazeron M.C., Perol Y. Oral acyclovir prophylactic treatment of herpes simplex infection after bone marrow transplantation. J Antimicrob Chemother. 12(Suppl. B):1983;161-167.
198. Greenberg M.S., Cohen S.G., Boosz B., Griedman H. Oral herpes simplex infection in patients with leukemia. J Am Dent Assoc. 114:1987;483-486.
199. Redding S.W. Role of herpes simplex virus reactivation in chemotherapy-induced oral mucositis. NCI Monogr. 9:1990;103-105.
200. Redding S.W., Montgomery M.T. Acyclovir prophylaxis for oral herpes simplex virus infection in patients with bone marrow transplants. Oral Surg. 67:1989;680-683.
201. Woo S.B., Sonis S.T., Sonis A.L. The role of herpes simplex virus in the development of oral mucositis in bone marrow transplant recipients. Cancer. 66:1990;2375-2379.
202. Epstein J.B., Ransier A., Sherlock C.H., Spinelli J.J., Reece D. Acyclovir prophylaxis of oral herpes virus during bone marrow transplantation. Eur J Cancer B Oral Oncol. 32B:1996;158-162.
203. Redding S.W., Montgomery M.T. Acyclovir prophylaxis for oral herpes simplex virus infection in patients with bone marrow transplants. Oral Surg Oral Med Oral Pathol. 67:1989;680-683.
204. Bubley G.J., Chapman B., Chapman S.K., Crumpacker C.S., Schnipper L.E. Effect of Acyclovir on radiation- and chemotherapy-induced mouth lesions. Antimicrob Agents Chemother. 33:1989;862-865.
205. Bergmann O.J., Mogensen S.C., Ellermann-Eriksen S., Ellegoard J. Acyclovir prophylaxis and fever during remission-induction therapy of patients with acute myeloid leukemia: a randomized, double blind, placebo -controlled trial. J Clin Oncol. 15:1997;2269-2274.
206. Newsholme E.A., Newsholme P., Curi R., Challoner E., Ardawi M.S.M. A role for muscle in the immune system and its importance in surgery, trauma, sepsis and burns. Nutrition. 4:1988;261-268.
207. Fürst P. Intracellular muscle free amino-acids; their measurement and function. Proc Nutr Soc. 42:1983;451-462.
208. Fürst P., Stehle P. The potential use of parenteral dipeptides in clinical nutrition. Nutr Clin Pract. 8:1993;106-114.
209. van der Hulst R.R.W.J., van Kreel B.K., von Meyenfeldt M.F., Brummer R.J.M., Arends J.W., Deutz N.E.P., Soeters P.B. Glutamine and the preservation of gut integrity. Lancet. 341:1993;1363-1365.
210. Higashiguchi T., Hasselgren P.O., Wagner K., Fischer J.E. Effect of glutamine on protein synthesis in isolated intestinal epithelial cells. J Parenter Enteral Nutr. 17:1993;307-314.
211. Fox A.D., Kripke S.A., de Paula J.A., Berman J.M., Settle R.G., Rombeau J.L. Effect of a glutamine-supplemented enteral diet on methotrexate-induced enterocolitis. J Parent Ent Nutr. 12:1988;325-331.
212. Skubitz K.M., Anderson P.M. Oral glutamine to prevent chemotherapy-induced stomatitis: a pilot study. J Lab Clin Med. 127:1996;223-228.
213. Anderson P.M., Schroeder G., Skubitz K.M. Oral glutamine reduces the duration and severity of stomatitis after cytotoxic cancer chemotherapy. Cancer. 83:1998;1433-1439.
214. van Zaanen H.C.T., van der Lelie H., Timmer J.G., Fürst P., Sauerwein H. Parenteral glutamine dipeptide supplementation does not ameliorate chemotherapy-induced toxicity. Cancer. 74:1994;2879-2884.
215. Jebb S.A., Osborne R.J., Maughan T.S., Mohideen N., Mack P., Mort D., Shelley M.D., Elia M. 5-fluorouracil and folinic acid-induced mucositis: no effect of oral glutamine supplementation. Br J Cancer. 70:1994;732-735.
216. Lissoni P., Tancini G., Barni S., Paolorossi F., Ardizzoia A., Conti A., Maestroni G. Treatment of cancer chemotherapy-induced toxicity with the pineal hormone melatonin. Support Care Cancer. 5:1997;126-129.
217. Wolfrom C., Hartmann R., Fengler R., Bruhmüller S., Ingwersen A., Henze G. Randomized comparison of 36-hour intermediate-dose versus 4-hour high-dose methotrexate infusions for remission induction in relapsed childhood acute lymphoblastic leukemia. J Clin Oncol. 11:1993;827-833.
218. Lévi F. Chronopharmacology of anticancer agents. Redfern P.H., Lemmer B. Handbook of Experimental Pharmacology: Physiology and Pharmacology of Biological Rhythms-Cancer Chemotherapy. 1997;299-331 Springer-Verlag, Berlin.
219. Smaaland R., Laerum O.D., Lote K., Sletvold O., Sothern R.B., Bjerknes R. DNA synthesis in human bone marrow is circadian stage dependent. Blood. 77:1991;2603-2611.
220. Smaaland R., Abrahamsen J.F., Svardal A.M., Lote K., Ueland P.M. DNA cell cycle distribution and glutathione (GSH) content according to circadian stage in bone marrow of cancer patients. Br J Cancer. 66:1992;39-45.
221. Lévi F., Zidani R., Misset J.L. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet. 350:1997;681-686.
222. 's-Gravenmade E.J. A survey of prevention and treatment regimens for oral sequelae resulting from head and neck radiotherapy used in Dutch radiotherapy institutes. Int J Radiat Oncol Biol Phys. 24:1992;359-367.
223. Mueller B.A., Millheim E.T., Farrington E.A., Brusko C., Wiser T.H. Mucositis management practices for hospitalized patients: national survey results. J Pain Symptom Manage. 10:1995;510-520.
224. Zimmermann JS, Wilhelm R, Niehoff P, Schneider R, Kovacs G, Kimmig B. Prophylaxe und Therapie akuter Strahlenfolgen an Haut und Schleimhaut. Teil I. Ergebnisse einer bundesweiten Erhebung. Strahlenther Onkol 1998;174:142-8.
225. Jacobson J.M., Greenspan J.S., Spritzler J., Ketter N., Fahey J.L., Jackson J.B., Fox L., Chernoff M., Wu A.W., MacPhail L.A., Vasquez G.J., Wohl D.A. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. N Engl J Med. 336:1997;1487-1493.